"Serotonin Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.
| Descriptor ID |
D012702
|
| MeSH Number(s) |
D27.505.519.625.850.850 D27.505.696.577.850.850
|
| Concept/Terms |
Serotonin Antagonists- Serotonin Antagonists
- 5-Hydroxytryptamine Antagonists
- 5 Hydroxytryptamine Antagonists
- Antagonists, 5-HT
- Antagonists, 5 HT
- Serotonin Receptor Blockers
- Blockers, Serotonin Receptor
- Receptor Blockers, Serotonin
- Antagonists, Serotonin
- Antiserotonergic Agents
- Agents, Antiserotonergic
- Serotonin Blockaders
- Blockaders, Serotonin
- Serotonin Receptor Antagonists
- Antagonists, Serotonin Receptor
- Receptor Antagonists, Serotonin
- 5-HT Antagonists
- 5 HT Antagonists
- Antagonists, 5-Hydroxytryptamine
- Antagonists, 5 Hydroxytryptamine
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Antagonists".
This graph shows the total number of publications written about "Serotonin Antagonists" by people in this website by year, and whether "Serotonin Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 1 | 4 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Antagonists" by people in Profiles.
-
Lam K, Peltz G, Kraft WK. The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets. Expert Opin Investig Drugs. 2025 Jan-Feb; 34(1-2):49-59.
-
Singh PM, Borle A, Gouda D, Makkar JK, Arora MK, Trikha A, Sinha A, Goudra B. Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis. J Clin Anesth. 2016 Nov; 34:459-82.
-
Yacoub HA, Johnson WG, Souayah N. Serotonin syndrome after administration of milnacipran for fibromyalgia. Neurology. 2010 Feb 23; 74(8):699-700.
-
Zhou D, Stack GP, Lo J, Failli AA, Evrard DA, Harrison BL, Hatzenbuhler NT, Tran M, Croce S, Yi S, Golembieski J, Hornby GA, Lai M, Lin Q, Schechter LE, Smith DL, Shilling AD, Huselton C, Mitchell P, Beyer CE, Andree TH. Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists. J Med Chem. 2009 Aug 13; 52(15):4955-9.
-
Ward SJ, Lefever TW, Rawls SM, Whiteside GT, Walker EA. Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats. Psychopharmacology (Berl). 2009 Sep; 206(1):155-65.
-
Beyer CE, Cremers TI. Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol. 2008 Feb 12; 580(3):350-4.
-
Zhang MY, Hughes ZA, Kerns EH, Lin Q, Beyer CE. Development of a liquid chromatography/tandem mass spectrometry method for the quantitation of acetylcholine and related neurotransmitters in brain microdialysis samples. J Pharm Biomed Anal. 2007 Jun 28; 44(2):586-93.
-
Kao T, Shumsky JS, Jacob-Vadakot S, Himes BT, Murray M, Moxon KA. Role of the 5-HT2C receptor in improving weight-supported stepping in adult rats spinalized as neonates. Brain Res. 2006 Sep 27; 1112(1):159-68.
-
Li SX, Pequignot E, Panebianco D, Lupinacci P, Majumdar A, Rosen L, Ahmed T, Royalty JE, Rushmore TH, Murphy MG, Petty KJ. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. J Clin Pharmacol. 2006 Jul; 46(7):792-801.
-
Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006; 53(3):157-68.